Free Trial
NASDAQ:EXEL

Exelixis (EXEL) Stock Price, News & Analysis

Exelixis logo
$43.68 +0.17 (+0.39%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Exelixis Stock (NASDAQ:EXEL)

Key Stats

Today's Range
$43.21
$44.02
50-Day Range
$36.17
$46.26
52-Week Range
$21.99
$49.62
Volume
940,878 shs
Average Volume
2.99 million shs
Market Capitalization
$11.91 billion
P/E Ratio
19.88
Dividend Yield
N/A
Price Target
$44.11
Consensus Rating
Hold

Company Overview

Exelixis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

EXEL MarketRank™: 

Exelixis scored higher than 94% of companies evaluated by MarketBeat, and ranked 70th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exelixis has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 12 buy ratings, 7 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Exelixis has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exelixis' stock forecast and price target.
  • Earnings Growth

    Earnings for Exelixis are expected to grow by 25.00% in the coming year, from $2.04 to $2.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exelixis is 19.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exelixis is 19.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.

  • Price to Earnings Growth Ratio

    Exelixis has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Exelixis has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exelixis' valuation and earnings.
  • Percentage of Shares Shorted

    7.73% of the float of Exelixis has been sold short.
  • Short Interest Ratio / Days to Cover

    Exelixis has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Exelixis has recently increased by 9.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Exelixis does not currently pay a dividend.

  • Dividend Growth

    Exelixis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.73% of the float of Exelixis has been sold short.
  • Short Interest Ratio / Days to Cover

    Exelixis has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Exelixis has recently increased by 9.56%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Exelixis has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Exelixis this week, compared to 16 articles on an average week.
  • Search Interest

    Only 21 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
  • MarketBeat Follows

    22 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,024,817.00 in company stock.

  • Percentage Held by Insiders

    Only 2.85% of the stock of Exelixis is held by insiders.

  • Percentage Held by Institutions

    85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exelixis' insider trading history.
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
What is Zacks Research's Estimate for Exelixis Q4 Earnings?
Peering Into Exelixis's Recent Short Interest
2 Stocks to Buy With Less Than $50
See More Headlines

EXEL Stock Analysis - Frequently Asked Questions

Exelixis' stock was trading at $33.30 at the start of the year. Since then, EXEL shares have increased by 31.3% and is now trading at $43.7270.

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Tuesday, February, 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.03. Exelixis had a trailing twelve-month return on equity of 28.81% and a net margin of 27.99%.
Read the conference call transcript
.

Exelixis' top institutional investors include Livforsakringsbolaget Skandia Omsesidigt (0.04%), Range Financial Group LLC (0.01%), Lifestyle Asset Management Inc. (0.01%) and Lingohr Asset Management GmbH (0.01%). Insiders that own company stock include David Edward Johnson, Stelios Papadopoulos, Christopher J Senner, Jeffrey Hessekiel, Dana Aftab, Amy C Peterson, Patrick J Haley, Peter Lamb, Jack L Wyszomierski, George Poste, Maria C Freire, Maria C Freire, Alan M Garber, Bob Oliver, Tomas J Heyman, Mary C Beckerle, Sue Gail Eckhardt and Carl B Feldbaum.
View institutional ownership trends
.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Humana (HUM), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
2/11/2025
Today
7/09/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXEL
CIK
939767
Employees
1,147
Year Founded
1994

Price Target and Rating

High Price Target
$60.00
Low Price Target
$29.00
Potential Upside/Downside
+1.0%
Consensus Rating
Hold
Rating Score (0-4)
2.48
Research Coverage
21 Analysts

Profitability

Trailing P/E Ratio
19.86
Forward P/E Ratio
21.41
P/E Growth
0.89
Net Income
$521.27 million
Pretax Margin
36.46%

Debt

Sales & Book Value

Annual Sales
$2.17 billion
Cash Flow
$1.90 per share
Price / Cash Flow
22.93
Book Value
$7.86 per share
Price / Book
5.56

Miscellaneous

Free Float
264,936,000
Market Cap
$11.91 billion
Optionable
Optionable
Beta
0.28

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:EXEL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners